Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.62 |
| ▸ | PDE5A | O76074 | 2/20 | 0.61 |
| ▸ | ACP1 | P24666 | 2/20 | 0.61 |
| ▸ | OGG1 | O15527 | 1/20 | 0.61 |
| ▸ | MERTK | Q12866 | 6/20 | 0.60 |
| ▸ | WHR1 | P49842 | 1/20 | 0.60 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.59 |
| ▸ | APP | P05067 | 2/20 | 0.56 |
| ▸ | BCHE | P06276 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
| ▸ | GBA1 | P04062 | 2/20 | 0.54 |
| ▸ | GRK6 | P43250 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24649614 | 0.87 | NPY5R (0.79) | NPY5RPDE5AACP1OGG1MERTK | |
| SCHEMBL27224044 | 0.82 | MERTK (0.81) | NPY5RPDE5AACP1OGG1MERTK | |
| SCHEMBL14256586 | 0.81 | MERTK (0.49) | NPY5RPDE5AACP1OGG1MERTK | |
| SCHEMBL24649760 | 0.80 | ACP1 (0.68) | NPY5RPDE5AACP1OGG1MERTK | |
| SCHEMBL24649772 | 0.80 | NPY5R (0.64) | NPY5RPDE5AACP1OGG1MERTK | |
| SCHEMBL30896233 | 0.80 | NPY5R (0.64) | NPY5RPDE5AACP1OGG1MERTK | |
| SCHEMBL24649781 | 0.78 | CXCR4 (0.63) | NPY5RPDE5AACP1OGG1MERTK | |
| SCHEMBL30896224 | 0.78 | CXCR4 (0.63) | NPY5RPDE5AACP1OGG1MERTK | |
| SCHEMBL30455430 | 0.77 | WHR1 (0.62) | NPY5RWHR1APPBCHEACHE | |
| SCHEMBL11732536 | 0.77 | ACP1 (0.68) | NPY5RPDE5AACP1OGG1MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080409-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | UNIVERSITY OF SOUTH FLORIDA (A FLORIDA NON-PROFIT CORPORATION) (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080409-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | UNIVERSITY OF SOUTH FLORIDA (A FLORIDA NON-PROFIT CORPORATION) (US) | 2015-03-19 | — | — | US | disclosed |
| US-8906918-B1 | Compositions, methods of use, and methods of treatment | UNIVERSITY OF SOUTH FLORIDA (A FLORIDA NON-PROFIT CORPORATION) (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906918-B1 | Compositions, methods of use, and methods of treatment | UNIVERSITY OF SOUTH FLORIDA (A FLORIDA NON-PROFIT CORPORATION) (US) | 2014-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080409-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | SYNCRIP, HNMT, IL5 | NPY5R 237/4885PDE5A 106/4885ACP1 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.